Breast Cancer | Clinical

Antiematics and Loperamide Resolve GI AEs Related to Oral Paclitaxel Plus Encequidar in mBC

December 12, 2020

Using 5- HT3 inhibitors and early intervention with loperamide was shown to manage gastrointestinal adverse events oral paclitaxel and encequidar in patients with metastatic breast cancer, according to a study presented during the San Antonio Breast Cancer Symposium.

Sacituzumab Govitecan Shows PFS Benefit for Patients With mTNBC and Brain Metastases

December 11, 2020

Sacituzumab govitecan led to improvements in response rates and progression-free survival (PFS) compared with chemotherapy for patients with metastatic triple-negative breast cancer who had stable brain metastases in a subgroup analysis from the phase 3 ASCENT trial.

Plinabulin/Pegfilgrastim Shows Improved Prevention of Profound Neutropenia in Breast Cancer Versus Chemotherapy

December 11, 2020

In the phase 3 PROTECTIVE-2 trial, patient with breast cancer who received plinabulin and pegfilgrastim experienced a reduction in the incidence of profound neutropenia that was 53% more effective than that of chemotherapy, according to findings presented during the 2020 San Antonio Breast Cancer Symposium.

GP2/GM-CSF Combination Induces 100% Disease-Free Survival Rate at 5 years in HER2 3+ Breast Cancer

December 11, 2020

The GP2 immunotherapy in combination with granulocyte-macrophage colony-stimulating factor induced a 100% disease-free survival with potent responses as treatment of patients with HER2/neu 3–positive disease who received adjuvant trastuzumab .

Adding Atezolizumab to Chemotherapy Improves Patient Outcomes in Early TNBC

December 11, 2020

Pathologic complete responses were improved when neoadjuvant atezolizumab was added to nab-paclitaxel followed by doxorubicin plus cyclophosphamide compared with placebo in combination with chemotherapy as treatment of patients with early triple-negative breast cancer without adding additional treatment burden to patients.

Ipatasertib Plus Paclitaxel Combo Fails to Improve PFS in PIK3CA/AKT1/PTEN-Altered TNBC

December 11, 2020

Ipatasertib in combination with paclitaxel failed to demonstrate a significant improvement in progression-free survival compared with placebo plus paclitaxel as treatment of patients with PIK3CA/AKT1/PTEN-altered locally advanced, unresectable or metastatic triple-negative breast cancer.

Clinical Benefit of Sacituzumab Govitecan in Metastatic TNBC Observed Irrespective of TROP-2 Expression

December 11, 2020

Sacituzumab govitecan demonstrated clinical benefit compared with physician’s choice of therapy as treatment of patients with metastatic triple-negative breast cancer, irrespective of Trop-2 expression, but greater efficacy was seen in patients with a medium or high Trop-2 score.

Pembrolizumab Added to Various Frontline Chemo Regimens Induces Antitumor Activity in Advanced TNBC

December 10, 2020

Subgroup analyses of a phase 3 randomized trial continue to support a role for the addition of pembrolizumab to chemotherapy in the frontline setting for patients with advanced triple-negative breast cancer, with the greatest benefit derived by those with higher PD-L1 expression by combined positive score.

Despite Challenges Becoming Pregnant for Breast Cancer Survivors, Babies Often Healthy With No Long-Term Survival Impact

December 10, 2020

Compared with women in the general population, those who survive breast cancer experience more difficulty in becoming pregnant and have a risk of preterm labor, although a systematic review and meta-analysis demonstrated that most deliver healthy babies with no detrimental effects on their long-term survival.